Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis

Patent metadata

Field	Value
Publication number	US-9499494-B2
Application number	US-201314046333-A
Country	US
Kind code	B2
Filing date	Oct 4, 2013
Priority date	May 5, 2009
Publication date	Nov 22, 2016
Grant date	Nov 22, 2016

Abstract

The present invention relates to the identification of inventive pyrimidine-2,4,6-triones (PYT compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the inventive PYT compounds.

First claim

What is claimed is:

1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:
L 1 is (C(R) 2 ) n — and wherein n is 2 to 5;
R 1 is phenyl, wherein R 1 is optionally substituted with p occurrences of R a , wherein p is 0 to 2, inclusive;
each R a is independently selected from the group consisting of —R, —OR, —CN, —NO 2 , —SR, —S(O)R, —SO 2 R, —C(O)R, —CO 2 R, —C(O)N(R) 2 , —NRC(O)R, —NRC(O)N(R) 2 , —NRSO 2 R, and —N(R) 2 , or wherein R a is an optionally substituted 5-6 membered monocyclic saturated, partially saturated, or aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered saturated, partially saturated, or aromatic bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
each R is independently hydrogen, halogen, optionally substituted C 1-6 aliphatic, optionally substituted phenyl, optionally substituted benzyl, or two R on the same nitrogen are taken together to form a 5-6 membered saturated, partially saturated, or aromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
except for L 1 and L 2 , where each R is independently hydrogen, halogen, optionally substituted phenyl, optionally substituted benzyl, or two R on the same nitrogen are taken together to form a 5-6 membered saturated, partially saturated, or aromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and except for R d where R c is phenyl and each R is independently hydrogen, optionally substituted phenyl, optionally substituted benzyl, or two R on the same nitrogen are taken together to form a 5-6 membered saturated, partially saturated, or aromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur

L 2 is —(C(R) 2 ) m — and wherein m is 2 to 5;
R 2 is phenyl wherein R 2 is optionally substituted with q occurrences of R b , wherein q is 0 to 2;
each R b is independently selected from the group consisting of —R, —OR, —CN, —NO 2 , —SR, —S(O)R, —SO 2 R, —C(O)R, —CO 2 R, —C(O)N(R) 2 , —NRC(O)R, —NRC(O)N(R) 2 , —NRSO 2 R, and —N(R) 2 , or wherein R b is an optionally substituted 5-6 membered monocyclic saturated, partially saturated, or aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered saturated, partially saturated, or aromatic bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R 3 and R 3′ are independently hydrogen or halogen, or R 3 and R 3′ are taken together to form a C 1 alkenylene optionally substituted with one or two R c groups;
each R c is independently —R, —OR, —CN, —NO 2 , —SR, —S(O)R, —SO 2 R, —C(O)R, —CO 2 R, —C(O)N(R) 2 , —NRC(O)R, —NRC(O)N(R) 2 , or —NRSO 2 R, or wherein R c is phenyl, a 5-6 membered monocyclic saturated, partially saturated, or aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered saturated, partially saturated, or aromatic bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein R c is optionally substituted with t occurrences of R d , wherein t is 0 to 5, inclusive; and
each R d is independently —R, —OR, —CN, —C(R) 3 , —NO 2 , —SR, —S(O)R, —SO 2 R, —C(O)R, —CO 2 R, —C(O)N(R) 2 , —NRC(O)R, —NRC(O)N(R) 2 , —NRSO 2 R, or —N(R) 2 ; providing said compound is not

2. The compound according to claim 1 , wherein said L 1 at least one R is independently halogen.

3. The compound according to claim 2 , wherein at least one R is independently fluorine.

4. The compound according to claim 1 , wherein R 1 is phenyl optionally substituted with R a .

5. The compound according to claim 4 , wherein at least one R a is independently halogen.

6. The compound according to claim 1 , wherein said L 2 at least one R is independently halogen.

7. The compound according to claim 6 , wherein at least one R is independently fluorine.

8. The compound according to claim 1 , wherein R 2 is phenyl optionally substituted with R b .

9. The compound according to claim 8 , wherein at least one R b is independently halogen.

10. The compound according to claim 1 , wherein at least one of R 3 or R 3′ is hydrogen.

11. The compound according to claim 1 , wherein at least one of R 3 or R 3′ is fluorine.

12. The compound according to claim 1 , of the following formula:

13. The compound according to claim 1 , of the following formula:

14. The compound according to claim 13 , wherein at least one R a is independently a halogen.

15. The compound according to claim 13 , wherein at least one R b is independently a halogen.

16. The compound according to claim 1 , wherein R 3 and R 3′ are taken together to form a C 1 alkenylene optionally substituted with one or two R c groups.

17. The compound according to claim 1 , of the formula:

18. The compound according to claim 1 , of the formula:

19. The compound according to claim 1 , of the formula:

20. The compound according to claim 19 , of the formula:

21. The compound according to claim 1 , of any one of the following formulae:

22. The compound according to claim 1 , of any one of the following formulae:

23. A pharmaceutical composition comprising:
a compound of claim 1 , and

Assignees

• Univ Northwestern

Inventors

• Kirsch Donald R
• Benmohamed Radhia
• Arvanites Anthony C
• Morimoto Richard I
• Xia Guoyao
• Silverman Richard B

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• C07D403/06

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title

• C07D413/06

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title

• C07D409/06

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title